Home › Funds › BAKER BROS. ADVISORS LP › RAPP
BAKER BROS. ADVISORS LP position in RAPP
RAPPORT THERAPEUTICS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 1,547,090 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$64.5M, representing 0.34% of its reported portfolio and ranking #32 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed RAPP holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's RAPP position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in RAPP in Q2 2025 at 550,090 shares (US$6.3M). The position peaked in Q2 2026 at 1,547,090 shares, worth US$64.5M. Across 5 filings, BAKER BROS. ADVISORS LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 1,547,090 shares valued at US$64.5M. Notable position changes include a 181% increase in Q3 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 550.09K | $6.25M | New |
| Q3 2025 | 1.55M | $45.95M | Add |
| Q4 2025 | 1.55M | $46.94M | Hold |
| Q1 2026 | 1.55M | $48.41M | Hold |
| Q2 2026 | 1.55M | $64.47M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RAPP and 13F data
RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Cormorant Asset Management, LP (US$110.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RAPP
- TRV GP V, LLC 6.28M sh · $261.71M · Q2 2026
- ARCH Venture Management, LLC 3.73M sh · $155.38M · Q2 2026
- Cormorant Asset Management, LP 2.66M sh · $110.74M · Q2 2026
- Sofinnova Investments, Inc. 1.90M sh · $79.36M · Q2 2026
- JOHNSON & JOHNSON 1.78M sh · $74.36M · Q2 2026
- TRV GP VI, LLC 969.22K sh · $40.39M · Q2 2026
- PERCEPTIVE ADVISORS LLC 773.34K sh · $32.23M · Q2 2026
- Vestal Point Capital, LP 730.00K sh · $30.42M · Q2 2026
- Siren, L.L.C. 641.47K sh · $26.73M · Q2 2026
- Sio Capital Management, LLC 307.66K sh · $12.82M · Q2 2026
- Burkehill Global Management, LP 250.00K sh · $10.42M · Q2 2026
- Artia Global Partners LP 138.51K sh · $5.77M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held RAPP?
BAKER BROS. ADVISORS LP has disclosed RAPP holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is BAKER BROS. ADVISORS LP's current position in RAPP?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 1.55M shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $64.47M, representing 0.34% of its reported portfolio and ranking #32.
Has BAKER BROS. ADVISORS LP been buying or selling RAPP?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in RAPP. The position peaked in Q2 2026 at 1.55M shares.
Which other funds hold RAPP?
Other major institutional holders of RAPP include TRV GP V, LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.